|
|
|
- れいな なぐも
- 9 years ago
- Views:
Transcription
1
2
3 IgE 1960 % %, % % 20 IgE 21 90% IgE IgE (%)
4 30 IgE 2. 3
5 1. B IgE T IgE IgE IgE 2 T IgE B IgE Th2 IgE Th1 Th1 Th2 Th1 IgE Th2 B IgE IL-4 T IL-12 Th2 Th1 IL-4, IL-13 IL-5, IL-10 IFN IL-2 IgE IgE B IgE IL-X = X 4 3. Th1 Th2 Th1 Th1 20 Th1 IgE Th2 1g 30 g B IgE IgE IgG 10 Th2 4 B IgE IgG IgA Th1 B IgE 2. IgE IgE 4
6 5 IgE IgE IgE 3. 1 Coombs 5 IgE IgE 4 Th2 B T IgE 6
7 50% 5% 10% 10 Th2 Th IgE T T Th2 Th
8 1. IgE 1996 IgE IgE IgG IgE IgE IgG IgE IgE IgE IgE IgE IgE 9 IgE 10 IgE IgE RAST (radio-allergo-solvent test) IgE IgE CAP-FEIA Alastat LUMIWARD Mast CAP 7
9 RAST 3 LUMIWARD CAP-FEIA MAST IgE IgE IgE IgE mm 5mm IgE IgE (C5a) Th2 (fmlp) CC (MCP-3 ) 3 &
10 1-10ng/ml CAP-FEIA 90% - 2. IgE IgE IgE 6 2,3 IgE IgE ECP IgE IgE IgE ECP (eosinophil cationic protein) ECP ECP ECP 13 ECP 9
11 mm Der 1 4 Der 1) g g Der 1 1g 9.46 g 1g 1.97 g 1g Der 1 2 g IgE 10 g ml 0.1ml 0.2ml 0.3ml 0.4ml 0.5ml ml 0.1ml 0.2ml 0.3ml 0.4ml 0.5ml 50% IgG IgE Th1 2. T IgE 10
12 B IgE 11
13 12 20 T Th
14 1. 20 mg/ml 1 mg/ml 13
15 2. 3. IgE 90% IgE IgE 70% 6% IgE A B C IgE IgE B C IgE 14
16 100% 90% 80% 70% T 5 major basic protein (MBP) eosinophil cationic protein (ECP) 2 P A 15
17 5 IgE 4. 90% 5 T T Th IgE 5 5 T IgE IgE T T 5 Th A2 Th2 Th IgE 5 16
18 T IgE RS cm RS ICAM-1 ICAM-1 RS ICAM-1 ICAM Mossad SB. Br. Med. J. 317:33,
19 IgE IgE RS RS 3 IgE 5 IgG2 IgG2 2 IgG2 cystic fibrosis 6. 1 PEF 18
20 NIH ml % T Th
21 IgE IgE Der 1 1g Der 1) Der 1) g/g IgE IgE Nishioka K, JACI IgE IgE IgE 1 IgE 20
22 2-3 3 RS 3 IgE 2 2,3 IgE RS IgE IgE
23 Der 1 1g 2 g IgE 10 g % ACTH (NK) 22
24 IgE 20 ECP T
25 BDP BDP 400 g 5cm 4cm 4cm T ATP AMP 5 -AMP A T
26 g BDP AMP AMP (5-20 g/ml) 2 2 AMP 25
27 26
28 2 1 1 RS RS IgE 85%
29 RS 29 RS
30 RS 3 RS ICAM-1 ICAM-1 IgE 7 T (Th2 ) Th Th1 Th
31 T 1 T B
32 3 90%
33 % 10% % 2% 1977 Hanifin 32
34 1994 Hanifin IgE IgE IgE IgE IgE T T IgE IgE
35 2. T T T IgE T Th1 Th1 IgG
36 Th1 3. IgE IgE IgE IgE IgE Th1 IgE Th2 20% T IgE IgE T IgE IgE IgE
37 IgE IgE IgE IgE 4. IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE 1 cm
38 37 95% Th1 Th2 IgE IgE IgE IgE T 35. T IgE T
39 5 T 38
40 A. B. B 39
41 2g 20g ,3 7,8 IgE IgE IgE 4 40
42 37. T T IgE IgE IgE 1 5, ,000 4,5 IgE
43 IgE IgE IgE IgE 7. 1) 1,1 IgE IgE IgE P P IgE 42
44 P IgE 80 2) IgE T T 43
45 44 1. IgE 1 7% 25% 2% 8% IgE
46 IgE IgE 30% IgE IgE 2,3 IgE 3. IgE 45
47 IgE Sampson IgE CAP-FEIA IgE 2-9kU/ml 90% 65kU/ml IgE IgE
48 1-2 IgE 3 IgE IgE 5,000 Hong IgE T T Th1 Th2 Th1, Th2 47
49 1. IgE
50 eotaxin
51 IgE 25 30% 70% 10 IgE 10,000IU/ml 1 IgE IgE 1 IgE 30 IgE IgE IgE IgE / DNA RNA mrna IgE 40 DNA RNA mrna mrna 6 13 mrna mrna RNA mrna 50
52 mrna mrna IgE TTACCCA TTAGCCA GeneChip, 1.2 cm mrna 42 DNA GeneChip) 41 Affymetrix DNA GeneChip 1.2cm 6, DNA CAGAGCTTG CAGTGCTTG CAGAGCTTG CAGTGCTTG GTCTCGAAT GTCACGAAT GTCTCGAAT GTCACGAAT CAGAGCUUG mrna CAGUGCUUG CAGAGCUUG CAGUGCUUG CCR5 SNP 43 SNP 44 SNP DNA 2000 mrna DNA 1% 1% 2,3 DNA DNA DNA 4 (single nucleotide polymorphism 51
53 SNP: ) 1 SNP SNP SNP 21 DNA 10 SNP: A SNP: B 45 52
54 SNP IgE IgE = Th1 IL-4, IL-13 IL-5, IL-10 Th2 Th2 IgE Th1 T IL-12 IFN B IgE Th2 Th1 IL-2 IL-X = X 47. DNA Th1 46 SNP CpG DNA Th1 Th1 Th1 CpG CpG CpG Th1 Th2 DNA DNA mrna 53
55 90% cystic fibrosis SNP 20 1 cystic fibrosis 30 SNP SNP SNP SNP SNP SNP 54
56 ,
57 1. T 1923 Coca IgG IgE 5, IgE 1966 IgE IgE 100 IgG IgE IgE 2. DNA B IgE 5% T T Thymus T T T T Th1 Th2 56
58 B Bursa B 1 B T IgE IgG Th1 Th2 2 T 1 Th1 2 Th2 Th Th1 Th1 12 Th2 100 IgE Th1 Th2 B B antigen antibody B IgG, IgA, IgM, IgE 4 IgG 1ml 13mg IgE 1ml 0.01mg Th2 B B B 4 13 IgE VCAM-1 Th1 B IgE T IgG IgG2 Th DNA CpG 2. IgE IgE Coombs Coombs Gell 1963 IgE IgE 57
59 IgG IgM SLE T 48 A2 C4, D4 C4 D4 3. Th2 Th1 Coombs GM-CSF IgG IgM 3 5 T B T T Th1 Th2 T T T B T 58
60 Th2 ECP C4 3 GM-CSF IgG IgE 0.5% IgE C4 B4 PAF 1 CC CXC CC eotaxin TNF 1 ICAM VCAM-1 ICAM-1 VCAM-1 59
61 DNA mrna major basic protein (MBP) eosinophil cationic protein (ECP) P A 4. 6 IgG2 IgG 4 IgG2 IgA IgE 2 ICAM-1 1 TNF 20-30nm RNA RS nm 60
62 AMP AMP Der 1 IgE Der 1 (1-10 ) Der p 1 Der f 1 Der ACTH 61
63 ACTH (NK) 12 Th1 0.9%NaCl 8. AMP 2 ATP AMP AMP A AMP AMP AMP DNA
64 IgE T T T 0.01% T 20% Th1 IgE Th2 IgE IgE Coombs T Th T T 63
65 1980 A FK506 FK ) IgE IgE IgE IgE IgE IgE IgE IgE B T DNA SLE, 2) 1. B Gad c 1 IgE Gad c 1 IgE Gad c Eotaxin MCP-1, RANTES MIP-1 CC. 4 DNA DNA A T G C A T G C DNA mrna 64
66 RNA mrna DNA RNA mrna T U mrna DNA RNA G C C G A U T A mrna mrna DNA mrna mrna 1 =1 DNA mrna transcription DNA 1.2cm 20 Affimetrix GeneChip cdna mrna Stanford cdna DNA mrna DNA SNP DNA mrna DNA mrna mrna mrna DNA DNA RNA DNA A T G C 4 RNA U A T(U), G C
67 IgE Nakagomi T, et al. Lancet 343: 121,1994. Erb KJ. Immunol. Today. 21: ,1999. Barnes KC, Marsh DG. Immunol. Today 19: 325, : 27, Greenberg RA et al. J. Pediatr. 114: 774, Murray AB et al. J. Allergy Clin. Immunol. 91: 102, Sporik R. et al. N. Eng. J. Med. 323:502, Kivity S et al. J Allergy Clin Immunol 91:844,1993. Platts-Mills TAE et al. Lancet 2:675,1982. Arshad SH et al. Lancet 339:1493, Nishioka K, et al. J. Allergy Clin. Immunol. 101:28, Iikura Y, et al. Ann. Allergy 68:233, Pedesen S, et al. Eur. Respir. J. 12:30, Sheffer AL et al. J Allergy Clin Immunol 88:425, Wolthers OD et al. Pediatr 1992;89:839. Barnes PJ Am Rev Respir Dis 1993; 48: 511. Busse WW. Am. J. Respir. Crit. Care Med. 151: 1675, Johnston SL: Clin. Exp. Allergy 1996; 26:989. Mossad SB. Br. Med. J. 317:33, KK 1994 Kraneveld AD, et al. Am. J. Respir. Crit. Care Med. 156:367,1997 Yasui K, et al. J. Clin. Invest. 100:1677,1997. Shichijo M, et al. J. Allergy Clin. Immunol. 103:421, : 1993;38:44 Nomura I, et al. J. Allergy Clin. Immunol. 104:441,1999. Th1 Th2 66
68 Grewe M et al.: Lancet. 343:25,1994 Sampson HA. J. Allergy Clin. Immunol. 103:717, Shicerer SH, Sampson HA. J. Allergy Clin. Immunol. 104:114, Hong SJ, et al. J. Allergy Clin. Immunol. 104:473,1999. Eotaxin Mochizuki M et al. J. Immunol. 160:60,1998 Fukagawa K, et al. J. Allergy Clin. Immunol. 103:1220, CpG Klinman DM, et al. Immunity 11:123, 1999 Hartmann G, et al. Proc. Natl. Acad. Sci. USA 96,9305, Chanock SJ, Foster CB. J. Clin. Invest. 104: ,1999 Silver LM Reiss M, Straughan R ( ): 1999 DNA
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.
untitled
~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/
2007050781......_.L.O...z.W
a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab
Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : [email protected] 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.
jcvp試験問題HP.indd
22 18 JCVP 1 G a e 1 G 1. A. B. C. D. P450 E. SOD c G 2. A. B. C. mrna D. E. G 3. G 4. A. B. ATP C. D. E. a A. B. C. 25 nm D. 10 nm E. 4 6 nm c d G 5. G 6. G 7. A. B. SOD C. D. E α E. d a. b. c. d. e.
ÿþ
インターロイキン インターロイキンは リンパ球や単球 マクロファージなどの免疫反応への寄与が知られる白血球から産生されることから 細胞間 ( inter-) 白血球 ( leukocyte -leukin) より Interleukin と名づけられました 現在までに 30 種類以上のインターロイキンが同定され 発見された順番に番号が付与されており 中にはケモカイン ( IL-8) やインターフェロン
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
ab c d 6 12 1:25,000 28 3 2-1-3 18 2-1-10 25000 3120 10 14 15 16 7 2-1-4 1000ha 10100ha 110ha ha ha km 200ha 100m 0.3 ha 100m 1m 2-1-11 2-1-5 20cm 2-1-12 20cm 2003 1 05 12 2-1-13 1968 10 7 1968 7 1897
2 (1) (2) SCI 2 SCI 2 24 2 12 2
2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1
) km 200 m ) ) ) ) ) ) ) kg kg ) 017 x y x 2 y 5x 5 y )
001 ) g 20 g 5 300 g 7 002 720 g 2 ) g 003 0.8 m 2 ) cm 2 004 12 15 1 3 1 ) 005 5 0.8 0.4 ) 6 006 5 2 3 66 ) 007 1 700 12 ) 008 0.315 ) 009 500 g ) kg 0.2 t 189 kg 17.1 kg 010 5 1 2 cm 3 cm )km 2-1 - 011
CAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
ŁRŁ¸•ñŁŁŁ‘
16 11 5 25mg 14 11 18 1 25mg 1 150,000 934 1 2 : 1-235-tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human γ1-chain Fc fragment), dimmer : : 1 235 236 467 G 1 γ1
VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
H26分子遺伝-20（サイトカイン）.ppt
第 20 回 サイトカイン 1. サイトカインとは 2014 年 11 月 12 日 附属生命医学研究所 生体情報部門 (1015 号室 ) 松田達志 ( 内線 2431) http://www3.kmu.ac.jp/bioinfo/ クラスI IL-2~7, IL-9, IL-11, IL-12, IL-13, IL-15, Epo, GM-CSF etc. クラスII IFN-α, IFN-β,
1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40
A case of membranoproliferative glomerulonephritis accompanied with hyper IgM immunodeficiency Kenichiro SHIGEMOTO, Koji WADA, Naoki HAMAGUCHI, Akira HIRABAYASHI, Shunji TOI, Koji USUI, Michiko ARITA,
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
1 1 2 2 3 3 4 5 5 6 6 7 7 8 8 9 9 10 10. 11 1 12 1 13 2 13 3 8 13 4 14 5 14 6 14 7 15 8 15 1 17 2 22 3 24 4 24 1 33 2 42 1 49 2 50 3 50 4 56 1 60 2 88 3 93 1 95 2 96 1 98 2 100 1 100 2 104 3 105 4 105
ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
日本皮膚科学会雑誌第120巻第5号
1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
10中西_他.indd
Streptomyces mobaraensis N N N Sm b Sm N N Sm Sm Sm ' ' Sm Sm ak K k K bk k K Sm Sm a b S. mobaraensis a b a b Sm b b bb b b Sm Sm S. lividans ab Sm ab Sm ab ab ab ab SmSm S. lividansab S. lividans ab
Single slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
L
-G -VG -G -VG.MPa..MPa.1MPa..MPa 1.5MPa 1.5MPa 1.5MPa 1.5MPa 1 s 5 5 - -V 1.51MPa 1.5MPa s s..mpa.mpa 1.5MPa 1.5MPa - -V 1 s s 5 5 1 JISg/H 1. 1.5. 11 SLLBFFB SLLBFTC CCCCBTC..MPa 1.5MPa SLLBFFB CCCCBTC
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
住まい・まちづくり活動事例集
3 H15 1982 1988 5 H16.31 1 1 1 246 26 3 2003 11 21,417/ 65 17.91% 16.62%1.29 246 2 1 12 1246 5008026 30080 3 200803 120060 2 20013 1 1 21 11 19821988 199112003 13 1988 1 1991 28 3 1991 1993 1992 1 1995
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
(a) (b) (c) (d) 1: (a) (b) (c) (d) (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4
![(a) (b) (c) (d) 1: (a) (b) (c) (d) (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4](/thumbs/91/105665060.jpg "(a) (b) (c) (d) 1: (a) (b) (c) (d) (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4")
1 vertex edge 1(a) 1(b) 1(c) 1(d) 2 (a) (b) (c) (d) 1: (a) (b) (c) (d) 1 2 6 1 2 6 1 2 6 3 5 3 5 3 5 4 4 (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4 1: Zachary [11] [12] [13] World-Wide
3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: [email protected] 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
からだにeヘルシーレシピ 高血圧
We b e 3,5 00 7day 1. 2. & 3. 1 C O N T E N T S 2.6 0 1 0 5 0 7 1 0 9 17 2 2 2 3 CHECK&POINT! 2 5 24 1 2 7 e 2 9 e 3 1 webe 3 3 6 12 18 24 6 16 16g 111 1 6 1 2010 2010 18 20 3,970 18 1 400 2.6 01 02 140mmHg
Taro10-名張１審無罪判決.PDF
-------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -1- 39 12 23 36 4 11 36 47 15 5 13 14318-2-
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
日本目録規則1987年版改訂2版第2章図書改定案
2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3
d-00
283-0105 298 TEL. 0475-76-0839 FAX. 0475-76-0838 400g 300 4950399167708 14 220g 300 4950399066780 Page 1 300g 200 4950399066766 100 400g 300 4950399167722 350g 160 4950399066735 100 600g 350 4950399167685
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
０９ Ｐ１０７〜１１８／木下 〃 芦塚 〃 稲
NK NK NK NK NK NK NK KT M NK NK KT M NK KT VTR SR SR SR SR SR SR KT NK NK FU M M A B C D E NK F G H I J I K M I I S R L L C C NKCL F C J J F M I J NK M M DY NK E E NK D D C D SR E D C C M NK NK SJ KK NK
コロイド化学と界面化学
x 25 1 kg 1 kg = 1 l mmol dm -3 ----- 1000 mg CO 2 -------------------------------------250 mg Li + --------------------------------1 mg Sr 2+ -------------------- 10
1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,
本文／ＡＹ３８０Ｊ
MHC-II II MHC-II MHC- II CD T T TCR T T MHC-II MHC-II T MHC-II MHC-II MHC-II MHC-II Ii Ii-MHC-II MHC-II antigen processing compartment MIIC Regulation of cell surface expression of MHC-II in dendritic
km2 km2 km2 km2 km2 22 4 H20 H20 H21 H20 (H22) (H22) (H22) L=600m L=430m 1 H14.04.12 () 1.6km 2 H.14.05.31 () 3km 3 4 5 H.15.03.18 () 3km H.15.06.20 () 1.1km H.15.06.30 () 800m 6 H.15.07.18
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
›Ê”÷„¤‰ƒ‘−…j…–†[…X
ISSN 1347-0345 National Institute of Fruit Tree Science 2003. 10 2 2003. 10 3 19761986 1989 5219 1997 19 12 10 250 270g Brix 15 160.5g/100ml 1590 10 2003. 10 4 DNA DNASSR 44 41SSR SSR Simple Sequence Repeat=
抗アレルギー効果のあるKW乳酸菌の発見と活用
KW3110 3 1 90 1983 6 1998 20 1989 Strachan BCG Lactobacillus Lactococcus Streptococcus Lactobacillus casei brevis johnsonii Th2 Th2 IL 4 B IgE IgE IgE IL-12 IL-12 Th1 Th1 Th2 Th2 Th1 Th2 KW 101 Th1/Th2
1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14
3 9 11 25 1 2 2 3 3 6 7 1 2 4 2 1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14 60 m3 60 m3 4 1 11 26 30 2 3 15 50 2 1 4 7 110 2 4 21 180 1 38
(1) (2) (3) (4) (5) (6) (7) 4 (8) (9) () LAN 1 2 3 ( ) () () () 30 20 5 5 450 450 5 5 30 10 20 15 36 30 6 6 450 450 6 6 36 8 30 14 50 35 20 20 450 450 20 20 50 8 35 14 100 70 20 20 450 450
c c & % c 0 c N r l % *# 5 c c% c c % c c c % % c % % % c j % % % % % % % % &% &% % a % a &% c % cc % & s& cc c c & c & % c & c c & % % %c c %c & c % & % %c c %c & c % % % % % c c c a 28 % c% 13 5 6
09-12-15_1203new
12 15 12/15 1/14 E _ GC DC Y FB GA BF Y 2 g g a f Y b b d b b c c b b g a c e b f b - Y b b c a c C A C C Y f g a b c d e - g a b c d c ab ab b g bb fbbd 3 4 1 F B 1 DF C A A A 6 G F A B 5 GA 6 E BF G